B7-H3 targeted CAR-T (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameB7-H3 targeted CAR-T (Fred Hutchinson Cancer Research Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFred Hutchinson Cancer Research Center

China Registration ClassN/A

Develop Information

Active CompaniesFred Hutchinson Cancer Research Center

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A